DrugPatentWatch Database Preview
Cumberland Pharms Company Profile
What is the competitive landscape for CUMBERLAND PHARMS, and what generic alternatives to CUMBERLAND PHARMS drugs are available?
There are fourteen US patents protecting CUMBERLAND PHARMS drugs.
There are seventy-seven patent family members on CUMBERLAND PHARMS drugs in twenty-one countries.
Summary for Cumberland Pharms
| International Patents: | 77 |
| US Patents: | 14 |
| Tradenames: | 5 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Cumberland Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumberland Pharms | ACETADOTE | acetylcysteine | INJECTABLE;INTRAVENOUS | 021539-001 | Jan 23, 2004 | AP | RX | Yes | Yes | 8,653,061 | ➤ Sign Up | ➤ Sign Up | |||
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-001 | Jun 11, 2009 | DISCN | No | No | 6,727,286 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Cumberland Pharms | LACTULOSE | lactulose | FOR SOLUTION;ORAL | 074712-001 | Dec 10, 1997 | RX | No | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-002 | Jun 11, 2009 | RX | Yes | Yes | 8,871,810 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for CUMBERLAND PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 200 mg/mL, 30 mL vials | ➤ Subscribe | 2012-04-04 |
Non-Orange Book US Patents for Cumberland Pharms
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 5,856,564 | Condensed benzazepine derivative and pharmaceutical composition thereof | ➤ Sign Up |
| 8,952,065 | Acetylcysteine composition and uses thereof | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Cumberland Pharms Drugs
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
